Aclaris Therapeutics ACRS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's cash & equivalents?
- Aclaris Therapeutics (ACRS) reported cash & equivalents of $28.66M in Q1 2026.
- How has Aclaris Therapeutics's cash & equivalents changed year-over-year?
- Aclaris Therapeutics's cash & equivalents decreased by 5.6% year-over-year, from $30.36M to $28.66M.
- What is the long-term trend for Aclaris Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's cash & equivalents has grown at a -2.0% compound annual growth rate (CAGR), from $22.06M to $19.96M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.